| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 57,990 | 53,167 | ||
| Accounts receivable, net | 22,187 | 23,955 | ||
| Inventories | 16,284 | 16,922 | ||
| Prepaid expenses and other current assets | 5,129 | 5,273 | ||
| Current assets held for sale | 0 | 0 | ||
| Total current assets | 101,590 | 99,317 | ||
| Property and equipment, net | 40,684 | 41,083 | ||
| Right-of-use assets | 24,226 | 24,722 | ||
| Other long-term assets | 5,507 | 5,550 | ||
| Notes receivable | 6,478 | 6,039 | ||
| Deferred tax assets | 1,251 | 1,254 | ||
| Intangible assets, net | 1,650 | 1,661 | ||
| Goodwill | 8,051 | 8,056 | ||
| Non-current assets held for sale | 0 | 0 | ||
| Total assets | 189,437 | 187,682 | ||
| Accounts payable | 4,732 | 4,771 | ||
| Accrued expenses and other current liabilities | 14,357 | 11,310 | ||
| Current liabilities held for sale | 0 | 0 | ||
| Total current liabilities | 19,089 | 16,081 | ||
| Other long-term liabilities | 761 | 756 | ||
| Lease liabilities | 22,782 | 23,173 | ||
| Non-current liabilities held for sale | 0 | 0 | ||
| Common stock, 0.01 par value 90,000 shares authorized, 15,355 issued and 14,421 outstanding and 15,010 issued and 14,416 outstanding at september 30, 2025 and december 31, 2024, respectively | 144 | 144 | ||
| Additional paid-in-capital | 91,105 | 89,459 | ||
| Accumulated other comprehensive loss | -4,939 | -4,755 | ||
| Retained earnings | 60,495 | 62,824 | ||
| Total stockholders equity | 146,805 | 147,672 | ||
| Total liabilities and stockholders equity | 189,437 | 187,682 | ||
Anika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc. (ANIK)